JP2008529558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008529558A5 JP2008529558A5 JP2007556383A JP2007556383A JP2008529558A5 JP 2008529558 A5 JP2008529558 A5 JP 2008529558A5 JP 2007556383 A JP2007556383 A JP 2007556383A JP 2007556383 A JP2007556383 A JP 2007556383A JP 2008529558 A5 JP2008529558 A5 JP 2008529558A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- nucleotide sequence
- amino acid
- fragment
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002773 nucleotide Substances 0.000 claims 60
- 125000003729 nucleotide group Chemical group 0.000 claims 60
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 239000012634 fragment Substances 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 230000002163 immunogen Effects 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65463205P | 2005-02-18 | 2005-02-18 | |
| US71272005P | 2005-08-29 | 2005-08-29 | |
| PCT/US2006/005913 WO2006089264A2 (en) | 2005-02-18 | 2006-02-17 | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116975A Division JP2012152228A (ja) | 2005-02-18 | 2012-05-22 | 髄膜炎／敗血症に関連する大腸菌由来のタンパク質および核酸 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008529558A JP2008529558A (ja) | 2008-08-07 |
| JP2008529558A5 true JP2008529558A5 (OSRAM) | 2009-04-02 |
Family
ID=36917149
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007556383A Pending JP2008529558A (ja) | 2005-02-18 | 2006-02-17 | 髄膜炎／敗血症に関連する大腸菌由来のタンパク質および核酸 |
| JP2012116975A Pending JP2012152228A (ja) | 2005-02-18 | 2012-05-22 | 髄膜炎／敗血症に関連する大腸菌由来のタンパク質および核酸 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116975A Pending JP2012152228A (ja) | 2005-02-18 | 2012-05-22 | 髄膜炎／敗血症に関連する大腸菌由来のタンパク質および核酸 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8758764B2 (OSRAM) |
| EP (2) | EP2351772B1 (OSRAM) |
| JP (2) | JP2008529558A (OSRAM) |
| AU (1) | AU2006214064B2 (OSRAM) |
| CA (1) | CA2601924A1 (OSRAM) |
| CY (2) | CY1117732T1 (OSRAM) |
| DK (2) | DK2351772T3 (OSRAM) |
| ES (2) | ES2595363T3 (OSRAM) |
| HU (2) | HUE030881T2 (OSRAM) |
| IL (2) | IL185359A0 (OSRAM) |
| LT (1) | LT2351772T (OSRAM) |
| MX (1) | MX306302B (OSRAM) |
| NZ (3) | NZ561042A (OSRAM) |
| PL (2) | PL1858920T3 (OSRAM) |
| PT (1) | PT2351772T (OSRAM) |
| SG (1) | SG160329A1 (OSRAM) |
| SI (2) | SI2351772T1 (OSRAM) |
| WO (1) | WO2006089264A2 (OSRAM) |
Families Citing this family (189)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4812942B2 (ja) * | 1999-02-26 | 2011-11-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強 |
| IL154853A0 (en) * | 2000-10-27 | 2003-10-31 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a & b |
| US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
| SI2351772T1 (sl) | 2005-02-18 | 2016-11-30 | Glaxosmithkline Biologicals Sa | Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso |
| KR20130122810A (ko) | 2005-06-27 | 2013-11-08 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 제조 방법 |
| US20100166788A1 (en) | 2006-08-16 | 2010-07-01 | Novartis Vaccines And Diagnostics | Immunogens from uropathogenic escherichia coli |
| ITMI20081249A1 (it) * | 2008-07-09 | 2010-01-09 | Novartis Vaccines & Diagnostic | Immunogeni di escherichia coli con solubilità migliorata. |
| JP5332237B2 (ja) * | 2008-03-06 | 2013-11-06 | 味の素株式会社 | Ｌ−システイン生産菌及びｌ−システインの製造法 |
| EP2331127A2 (en) | 2008-09-18 | 2011-06-15 | Novartis AG | Vaccine adjuvant combinations |
| US8647642B2 (en) | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
| WO2010124085A2 (en) * | 2009-04-23 | 2010-10-28 | Cornell University | Compositions and methods for preventing and treating uterine disease |
| US9119802B2 (en) * | 2009-05-06 | 2015-09-01 | Cornell University | E. coli LpfA antigen for prevention and treatment of infectious diseases |
| ITMI20090946A1 (it) | 2009-05-28 | 2010-11-29 | Novartis Ag | Espressione di proteine ricombinanti |
| ES2596653T3 (es) | 2009-06-16 | 2017-01-11 | Glaxosmithkline Biologicals Sa | Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento |
| SG177533A1 (en) | 2009-07-07 | 2012-02-28 | Novartis Ag | Conserved escherichia coli immunogens |
| PT2464658E (pt) | 2009-07-16 | 2015-01-14 | Novartis Ag | Imunogénios de escherichia coli desintoxicados |
| EP2277989A1 (en) | 2009-07-24 | 2011-01-26 | Technische Universiteit Delft | Fermentative glycerol-free ethanol production |
| EP2470205A1 (en) * | 2009-08-27 | 2012-07-04 | Novartis AG | Adjuvant comprising aluminium, oligonucleotide and polycation |
| JP5988492B2 (ja) | 2009-09-02 | 2016-09-07 | ノバルティス アーゲー | Ｔｌｒ活性モジュレーターを含む免疫原性組成物 |
| ES2387719T3 (es) * | 2009-09-10 | 2012-09-28 | Freie Universität Berlin | Identificación y caracterización de una nueva adhesina fimbrial de E. coli patógena aviar (APEC) |
| WO2011039382A1 (en) * | 2009-10-02 | 2011-04-07 | Oslo Universitetssykehus Hf | Antibacterial polypeptides and use thereof |
| US8741591B2 (en) | 2009-10-09 | 2014-06-03 | The Research Foundation For The State University Of New York | pH-insensitive glucose indicator protein |
| PL2509961T3 (pl) | 2009-12-11 | 2016-09-30 | Pochodne imidazolidynodionu | |
| JP5781542B2 (ja) * | 2009-12-30 | 2015-09-24 | ノバルティス アーゲー | Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原 |
| PL2591114T3 (pl) | 2010-07-06 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Immunizacja dużych ssaków małymi dawkami rna |
| PT3243526T (pt) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | Distribuição de arn para despoletar múltiplas vias imunitárias |
| FI4005592T3 (fi) | 2010-07-06 | 2023-01-13 | Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille | |
| AU2011276234B2 (en) | 2010-07-06 | 2016-02-25 | Glaxosmithkline Biologicals S.A. | Liposomes with lipids having an advantageous pKa- value for RNA delivery |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| AU2011295938B2 (en) | 2010-08-31 | 2016-01-14 | Glaxosmithkline Biologicals S.A. | Lipids suitable for liposomal delivery of protein-coding RNA |
| PT3981427T (pt) | 2010-08-31 | 2022-06-27 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para entrega de arn codificador de imunogénio |
| CN105999275A (zh) | 2010-09-01 | 2016-10-12 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
| CA2810971C (en) | 2010-09-10 | 2020-11-03 | Novartis Ag | Developments in meningococcal outer membrane vesicles |
| TR201903651T4 (tr) | 2010-10-11 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Antijen uygulama platformları. |
| EP2652511B8 (en) | 2010-12-14 | 2017-06-28 | GlaxoSmithKline Biologicals SA | Flow cytometry analysis of materials adsorbed to metal salts |
| EP2667852B1 (en) | 2011-01-27 | 2016-11-09 | GlaxoSmithKline Biologicals SA | Adjuvant nanoemulsions with crystallisation inhibitors |
| US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
| US10010568B2 (en) | 2011-02-04 | 2018-07-03 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a spirochetes infection in a human being |
| US10111913B2 (en) | 2011-02-04 | 2018-10-30 | Joseph E. Kovarik | Method of reducing the likelihood of skin cancer in an individual human being |
| US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| US11191665B2 (en) | 2011-02-04 | 2021-12-07 | Joseph E. Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US10940169B2 (en) | 2015-11-30 | 2021-03-09 | Joseph E. Kovarik | Method for reducing the likelihood of developing cancer in an individual human being |
| US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
| US10835560B2 (en) | 2013-12-20 | 2020-11-17 | Joseph E. Kovarik | Reducing the likelihood of skin cancer in an individual human being |
| US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
| US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
| US11357722B2 (en) | 2011-02-04 | 2022-06-14 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US12279989B2 (en) | 2011-02-04 | 2025-04-22 | Seed Health, Inc. | Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity |
| US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
| US12257272B2 (en) | 2015-12-24 | 2025-03-25 | Seed Health, Inc. | Method and system for reducing the likelihood of developing depression in an individual |
| US10583033B2 (en) | 2011-02-04 | 2020-03-10 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US10085938B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for preventing sore throat in humans |
| US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| CA2828844C (en) | 2011-03-02 | 2020-07-14 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| EP2688590B1 (en) | 2011-03-24 | 2020-02-12 | GlaxoSmithKline Biologicals SA | Adjuvant nanoemulsions with phospholipids |
| CN103764121A (zh) | 2011-07-06 | 2014-04-30 | 诺华股份有限公司 | 用于递送rna分子的具有有用n:p比的脂质体 |
| EP2729165B1 (en) | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| BR112014004607A2 (pt) | 2011-08-31 | 2017-03-21 | Novartis Ag | lipossomas peguilados para entrega de rna codificado imunogênico |
| WO2013038385A2 (en) | 2011-09-14 | 2013-03-21 | Novartis Ag | Escherichia coli vaccine combination |
| KR101359844B1 (ko) * | 2012-01-06 | 2014-02-25 | 씨제이제일제당 (주) | 퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법 |
| EP2806026B1 (en) * | 2012-01-18 | 2018-12-26 | Mitsui Chemicals, Inc. | Method for producing 1,5-pentamethylenediamine, mutant lysine decarboxylase, method for producing 1,5-pentamethylene diisocyanate and method for producing polyisocyanate composition |
| CN104203946B (zh) | 2012-03-07 | 2017-03-22 | 诺华股份有限公司 | 免疫上有用的精氨酸盐 |
| CN104519910B (zh) | 2012-03-07 | 2017-05-03 | 诺华股份有限公司 | 肺炎链球菌抗原的含佐剂制剂 |
| AU2013229432A1 (en) | 2012-03-08 | 2014-10-16 | Novartis Ag | Adjuvanted formulations of booster vaccines |
| US9758571B2 (en) * | 2012-07-20 | 2017-09-12 | University—Industry Cooperation Group Of Kyung Hee University | Antibody for epitope tagging, hybridoma cell line and uses thereof |
| EP3400960A1 (en) | 2012-09-18 | 2018-11-14 | GlaxoSmithKline Biologicals S.A. | Outer membrane vesicles |
| ES2821383T3 (es) * | 2012-10-17 | 2021-04-26 | Enterome | Firmas genéticas de trastornos inflamatorios relacionados con el hígado y la enfermedad de Crohn |
| US10288610B2 (en) * | 2012-11-13 | 2019-05-14 | The General Hospital Corporation | Vitro assays for detecting Salmonella enterica serotype typhi |
| WO2014102694A1 (en) | 2012-12-24 | 2014-07-03 | Novartis Ag | Novel mucinase for use in therapy or prophylaxis |
| EA201891018A1 (ru) | 2013-03-08 | 2018-09-28 | Новартис Аг | Липиды и липидные композиции для доставки активных агентов |
| US10760064B2 (en) | 2013-03-15 | 2020-09-01 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
| WO2014204578A1 (en) | 2013-06-21 | 2014-12-24 | The General Hospital Corporation | Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing |
| KR102271292B1 (ko) | 2013-03-15 | 2021-07-02 | 더 제너럴 하스피탈 코포레이션 | Rna-안내 게놈 편집의 특이성을 증가시키기 위한 rna-안내 foki 뉴클레아제(rfn)의 용도 |
| KR101525663B1 (ko) * | 2013-05-10 | 2015-06-04 | 씨제이제일제당 (주) | 신규 ｏ-포스포세린 배출 단백질 및 이를 이용한 ｏ-포스포세린의 생산방법 |
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| EP3027205A4 (en) * | 2013-07-28 | 2017-07-19 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
| KR20150018227A (ko) * | 2013-08-09 | 2015-02-23 | 삼성전자주식회사 | 외인성 푸마라아제 유전자를 포함하는 코리네박테리움 및 이를 이용한 c4 디카르복실산의 생산 방법 |
| US11248040B2 (en) | 2013-09-26 | 2022-02-15 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
| CN111218447B (zh) | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| EP4019506A1 (en) | 2013-12-19 | 2022-06-29 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| ES2774968T3 (es) | 2013-12-19 | 2020-07-23 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
| US11529379B2 (en) | 2013-12-20 | 2022-12-20 | Seed Health, Inc. | Method and system for reducing the likelihood of developing colorectal cancer in an individual human being |
| US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
| US12246043B2 (en) | 2013-12-20 | 2025-03-11 | Seed Health, Inc. | Topical application to treat acne vulgaris |
| US12329783B2 (en) | 2013-12-20 | 2025-06-17 | Seed Health, Inc. | Method and system to improve the health of a person's skin microbiome |
| US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
| US11672835B2 (en) | 2013-12-20 | 2023-06-13 | Seed Health, Inc. | Method for treating individuals having cancer and who are receiving cancer immunotherapy |
| US11213552B2 (en) | 2015-11-30 | 2022-01-04 | Joseph E. Kovarik | Method for treating an individual suffering from a chronic infectious disease and cancer |
| US11642382B2 (en) | 2013-12-20 | 2023-05-09 | Seed Health, Inc. | Method for treating an individual suffering from bladder cancer |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US12318377B2 (en) | 2013-12-20 | 2025-06-03 | Seed Health, Inc. | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| US11026982B2 (en) | 2015-11-30 | 2021-06-08 | Joseph E. Kovarik | Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being |
| US10624934B2 (en) | 2014-03-06 | 2020-04-21 | Research Institute At Nationwide Children's Hospital | Prebiotic formulations |
| AU2015227075A1 (en) | 2014-03-06 | 2016-09-22 | Ohio State Innovation Foundation | Probiotic formulations and methods for use |
| CL2014001126A1 (es) * | 2014-04-29 | 2014-08-29 | Univ Chile | Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec. |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| ES2969956T3 (es) | 2014-09-05 | 2024-05-23 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| US10858675B2 (en) * | 2015-04-07 | 2020-12-08 | Metabolic Explorer | Modified microorganism for the optimized production of 2,4-dihydroxybutyrate with enhanced 2,4-dihydroxybutyrate efflux |
| US20160317615A1 (en) * | 2015-05-01 | 2016-11-03 | Jose Javier Lopez GONZALEZ | T cell modulator |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11209972B2 (en) | 2015-09-02 | 2021-12-28 | D&M Holdings, Inc. | Combined tablet screen drag-and-drop interface |
| WO2016210384A2 (en) | 2015-06-25 | 2016-12-29 | Synlogic, Inc. | Bacteria engineered to treat metabolic diseases |
| WO2017023863A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
| US9926546B2 (en) | 2015-08-28 | 2018-03-27 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| WO2017066719A2 (en) | 2015-10-14 | 2017-04-20 | Research Institute At Nationwide Children's Hospital | Hu specific interfering agents |
| EP3378934B1 (en) * | 2015-11-16 | 2023-07-05 | National University Corporation Kumamoto University | Composition inducing cell reprogramming and producing method for cells having pluripotency using said composition |
| US10933128B2 (en) | 2015-11-30 | 2021-03-02 | Joseph E. Kovarik | Method and system for protecting honey bees from pesticides |
| US11529412B2 (en) | 2015-11-30 | 2022-12-20 | Seed Health, Inc. | Method and system for protecting honey bees from pesticides |
| US10086024B2 (en) | 2015-11-30 | 2018-10-02 | Joseph E. Kovarik | Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides |
| US12239706B2 (en) | 2015-11-30 | 2025-03-04 | Seed Health, Inc. | Method and system for protecting monarch butterflies from pesticides |
| US10568916B2 (en) | 2015-11-30 | 2020-02-25 | Joseph E. Kovarik | Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides |
| US10675347B2 (en) | 2015-11-30 | 2020-06-09 | Joseph E. Kovarik | Method and system for protecting honey bees from fipronil pesticides |
| US11519016B2 (en) | 2016-01-21 | 2022-12-06 | T2 Biosystems, Inc. | NMR methods and systems for the rapid detection of bacteria |
| US11155578B2 (en) | 2016-02-17 | 2021-10-26 | Pepticom Ltd. | Peptide agonists and antagonists of TLR4 activation |
| EP3430168B1 (en) * | 2016-03-14 | 2021-10-20 | The Translational Genomics Research Institute | Methods and kits to identify klebsiella strains |
| WO2017158135A1 (en) * | 2016-03-16 | 2017-09-21 | Dsm Ip Assets B.V. | Microbial production of nicotinic acid riboside |
| WO2017185249A1 (zh) * | 2016-04-27 | 2017-11-02 | 拜西欧斯（北京）生物技术有限公司 | 兴奋性神经毒性相关损伤的治疗肽 |
| GB201617548D0 (en) * | 2016-10-17 | 2016-11-30 | Linnane Pharma Ab | Novel biological factor |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| MX2019007910A (es) | 2016-12-30 | 2019-12-05 | Sutrovax Inc | Conjugados de polipeptido-antigeno con aminoacidos no naturales. |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| WO2018129092A1 (en) | 2017-01-04 | 2018-07-12 | Research Institute At Nationwide Children's Hospital | Antibody fragments for the treatment of biofilm-related disorders |
| AU2018206552C1 (en) | 2017-01-04 | 2025-04-10 | Research Institute At Nationwide Children's Hospital | DNABII vaccines and antibodies with enhanced activity |
| WO2018200894A1 (en) | 2017-04-28 | 2018-11-01 | Intrexon Corporation | Methods and microorganisms for the fermentation of methane to multi-carbon compounds |
| KR101943081B1 (ko) * | 2017-08-31 | 2019-01-29 | (주)케어젠 | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 |
| US20190233816A1 (en) | 2018-01-26 | 2019-08-01 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
| JP7493248B2 (ja) * | 2018-07-09 | 2024-05-31 | コデクシス， インコーポレイテッド | 操作されたホスホペントムターゼ改変体酵素 |
| US12150967B2 (en) | 2018-08-18 | 2024-11-26 | Seed Health, Inc. | Methods and compositions for honey bee health |
| EP3860718A4 (en) | 2018-10-05 | 2022-08-31 | Research Institute at Nationwide Children's Hospital | HMGB1 PROTEIN DERIVATIVES FOR BIOFILM REMOVAL |
| WO2020073004A1 (en) | 2018-10-05 | 2020-04-09 | Research Institute At Nationwide Children's Hospital | Compositions and methods for enzymatic disruption of bacterial biofilms |
| KR101991207B1 (ko) | 2018-11-29 | 2019-06-19 | 씨제이제일제당 (주) | cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법 |
| KR101991206B1 (ko) * | 2018-11-29 | 2019-06-19 | 씨제이제일제당 (주) | cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법 |
| KR101996767B1 (ko) * | 2018-11-29 | 2019-07-04 | 씨제이제일제당 (주) | cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법 |
| JP7558167B2 (ja) | 2018-12-03 | 2024-09-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | オリゴベンズアミド類似体およびがん処置におけるそれらの使用 |
| JP2022513709A (ja) * | 2018-12-10 | 2022-02-09 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 非染色体性動的活性システム |
| WO2020234498A2 (es) * | 2019-05-15 | 2020-11-26 | Universidad De Granada | Terapia génica con los genes hokd y ldrb para el tratamiento del cáncer |
| JP7662538B2 (ja) | 2019-06-03 | 2025-04-15 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 敗血症および壊死性腸炎誘発神経発達不全の予防のためのプレバイオティクス製剤 |
| EP3986909A4 (en) * | 2019-06-21 | 2023-08-02 | Inscripta, Inc. | Genome-wide rationally-designed mutations leading to enhanced lysine production in e. coli |
| CN110441284B (zh) * | 2019-07-23 | 2022-02-15 | 海南大学 | 一种可用于痕量检测的表面增强拉曼散射芯片的制备方法及所得产品和应用 |
| KR102183209B1 (ko) * | 2019-09-09 | 2020-11-26 | 씨제이제일제당 주식회사 | L-쓰레오닌 배출 단백질의 변이체 및 이를 이용한 l-쓰레오닌 생산 방법 |
| JP7735863B2 (ja) * | 2019-10-28 | 2025-09-09 | 味の素株式会社 | ベンズアルデヒドの製造方法 |
| KR20220119408A (ko) * | 2019-12-20 | 2022-08-29 | 바스프 에스이 | 터펜의 독성 감소 및 미생물에서 생산 잠재성 증가 |
| US20230105474A1 (en) * | 2020-02-25 | 2023-04-06 | Synlogic Operating Company, Inc. | Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof |
| CN111778224B (zh) * | 2020-07-20 | 2021-06-01 | 成都薇合生物科技有限公司 | 尿酸酶或其同源酶及其应用 |
| CA3191900A1 (en) * | 2020-08-28 | 2022-03-03 | Codexis, Inc. | Engineered amylase variants |
| WO2022076454A1 (en) * | 2020-10-07 | 2022-04-14 | Codexis, Inc. | Engineered phosphopentomutase variant enzymes |
| CN112391331B (zh) * | 2020-11-12 | 2022-09-27 | 江南大学 | 一种过表达GatA基因的重组大肠杆菌及其应用 |
| KR102792504B1 (ko) * | 2020-12-28 | 2025-04-09 | 대상 주식회사 | 히스티딘에 의한 피드백 억제가 감소된 atp-prt 변이체 및 이를 발현하는 히스티딘 생산 균주 |
| CN114137209B (zh) * | 2021-02-01 | 2024-03-01 | 中国水产科学研究院黄海水产研究所 | 一种快速检测牡蛎疱疹病毒抗原的免疫荧光检测试纸条及应用 |
| US11452757B2 (en) * | 2021-02-25 | 2022-09-27 | Intron Biotechnology, Inc. | Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same |
| JP2024514074A (ja) | 2021-04-01 | 2024-03-28 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | Ｅ．ｃｏｌｉ ｏ１８バイオコンジュゲートの産生 |
| KR102707457B1 (ko) * | 2021-06-11 | 2024-09-20 | 씨제이제일제당 주식회사 | 신규한 MdtH 변이체 및 이를 이용한 O-포스포세린, 시스테인 및 이의 유도체의 생산방법 |
| WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| EP4387597A1 (en) | 2021-08-16 | 2024-06-26 | GlaxoSmithKline Biologicals SA | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| US20250137050A1 (en) * | 2021-08-18 | 2025-05-01 | The Regents Of The University Of California | Methods and compositions for determining risk of autism spectrum disorders |
| CN113897324B (zh) * | 2021-10-13 | 2023-07-28 | 云南师范大学 | 一种用作抗锰剂的JcVIPP1重组大肠杆菌及其构建方法 |
| CN114107413B (zh) * | 2021-11-03 | 2023-10-20 | 江苏香地化学有限公司 | 一种酶催化胞嘧啶生产胞苷的方法及应用 |
| US11548917B1 (en) * | 2021-11-24 | 2023-01-10 | Intron Biotechnology, Inc. | Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same |
| CN119031940A (zh) * | 2021-12-21 | 2024-11-26 | 思研（Sri）国际顾问与咨询公司 | 中枢神经系统细胞特异性递送的双重靶向 |
| CN114522230A (zh) * | 2022-01-11 | 2022-05-24 | 上海市伤骨科研究所 | 一种蓝光和对苯醌联合杀菌方法 |
| WO2023139605A1 (en) * | 2022-01-20 | 2023-07-27 | Techinvention Lifecare Pvt. Ltd. | Lysin polypeptides and compositions thereof against urinary tract infection caused by drug-resistant gram- negative bacteria |
| CN115286701A (zh) * | 2022-03-07 | 2022-11-04 | 江苏靶标生物医药研究所有限公司 | 一种调节哺乳动物的肠道粘膜稳态或炎症性肠病的靶点及其应用 |
| US20240003886A1 (en) * | 2022-06-15 | 2024-01-04 | Quantum-Si Incorporated | Directed protein evolution |
| WO2024073730A2 (en) * | 2022-09-29 | 2024-04-04 | The University Of Chicago | Methods and systems for rna sequencing and analysis |
| CA3270165A1 (en) | 2022-10-19 | 2024-04-25 | Glyprovac Aps | Glycosylated YGHJ polypeptides from uropathogenic E. coli |
| CN118086235A (zh) * | 2022-11-28 | 2024-05-28 | 宁波酶赛生物工程有限公司 | 一种合成d-泛解酸的酶催化剂和方法 |
| KR20240120829A (ko) * | 2023-01-31 | 2024-08-08 | 대상 주식회사 | 망가니즈 익스포터 신규 변이체 및 이를 이용한 l-히스티딘 생산 방법 |
| GB202303019D0 (en) | 2023-03-01 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Method of lyophilisation |
| WO2025017339A1 (en) * | 2023-07-14 | 2025-01-23 | Iowa State University Research Foundation, Inc. | Escherichia coli nhaa membrane protein drug target and immunogenic compositions therefrom |
| CN116949027B (zh) * | 2023-07-19 | 2024-12-24 | 浙江中医药大学 | 一种尿路致病性大肠埃希菌重组蛋白组合物ls、其构建、表达、纯化方法及其应用 |
| GB202311382D0 (en) | 2023-07-25 | 2023-09-06 | Glaxosmithkline Biologicals Sa | Lyophilised compostion |
| WO2025219177A1 (en) | 2024-04-18 | 2025-10-23 | Glyprovac Aps | Optimized plasmids for expression of yghj polypeptides |
| CN118388664B (zh) * | 2024-05-21 | 2024-12-03 | 广东省农业科学院动物卫生研究所 | 副猪嗜血杆菌融合抗原及其应用 |
| CN119061031A (zh) * | 2024-10-08 | 2024-12-03 | 安徽农业大学 | 一种水稻抗除草剂突变基因及其应用 |
Family Cites Families (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| AU631377B2 (en) | 1988-08-25 | 1992-11-26 | Liposome Company, Inc., The | Affinity associated vaccine |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| FI920131A0 (fi) | 1989-07-14 | 1992-01-13 | Praxis Biolog Inc | Cytokin- och hormonbaerare foer konjugatvaccin. |
| US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| DE69113564T2 (de) | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. |
| UA32546C2 (uk) | 1991-03-01 | 2001-02-15 | Міннесота Майнінг Енд Мен'Юфекчурінг Компані | 1,2-заміщені 1н-імідазо[4,5-с]хінолін-4-аміни, проміжні сполуки для їх синтезу, антивірусна фармацевтична композиція, спосіб лікування інфікованих ссавців, спосіб індукування біосинтезу інтерферону у ссавців, спосіб уповільнення росту бластом |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| EP0671948B1 (en) | 1992-06-25 | 1997-08-13 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| ES2109685T5 (es) | 1993-03-23 | 2005-09-01 | Smithkline Beecham Biologicals S.A. | Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado. |
| ES2145072T3 (es) | 1993-05-13 | 2000-07-01 | American Cyanamid Co | Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos. |
| ATE195735T1 (de) | 1993-07-15 | 2000-09-15 | Minnesota Mining & Mfg | Imidazo (4,5-c)pyridin-4-amine |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| AU6489996A (en) | 1995-07-14 | 1997-02-18 | Somatogen, Inc. | Methods for increasing protein expression |
| US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| US6316609B1 (en) * | 1996-11-22 | 2001-11-13 | Human Genome Sciences, Inc. | Nucleotide sequence of Escherichia coli pathogenicity islands |
| EP2172216A3 (en) | 1997-03-10 | 2010-11-24 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| DE69838992T2 (de) | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
| CA2671261A1 (en) | 1997-11-06 | 1999-05-20 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigens |
| AU762606B2 (en) | 1997-11-21 | 2003-06-26 | Genset S.A. | Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| BR9906927A (pt) | 1998-01-14 | 2001-11-20 | Chiron Spa | Proteìnas de neisseria meningitidis |
| WO1999040936A2 (en) | 1998-02-12 | 1999-08-19 | American Cyanamid Company | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| WO1999052549A1 (en) | 1998-04-09 | 1999-10-21 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
| NZ532665A (en) | 1998-05-01 | 2005-11-25 | Inst Genomic Research | Neisseria meningitidis antigens and compositions |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| EP1105495B2 (en) | 1998-08-14 | 2009-01-21 | Novartis Vaccines and Diagnostics, Inc. | Method for producing yeast expressed hpv types 6 and 16 capsid proteins |
| DK1126876T3 (da) | 1998-10-16 | 2007-07-02 | Glaxosmithkline Biolog Sa | Adjuvanssystemer og vacciner |
| AU1722300A (en) | 1998-11-12 | 2000-05-29 | Regents Of The University Of California, The | Chlamydia pneumoniae genome sequence |
| WO2002016439A2 (en) | 2000-03-07 | 2002-02-28 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| IL145043A0 (en) | 1999-03-19 | 2002-06-30 | Smithkline Beecham Biolog | Vaccine |
| EP1165140B1 (en) | 1999-03-26 | 2004-08-04 | Vical Incorporated | Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines |
| JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア |
| BR0010361A (pt) | 1999-04-30 | 2003-06-10 | Chiron Corp | Seq ências genÈmicas de neisseria e uso destas |
| WO2000068253A1 (en) | 1999-05-05 | 2000-11-16 | Sterrenbeld Biotechnologie North America, Inc. | Dna promoter sequence for gene expression |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| CA2383110A1 (en) | 1999-09-24 | 2001-03-29 | Veronique Henderickx | Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant |
| EP1221971A2 (en) | 1999-09-24 | 2002-07-17 | SmithKline Beecham Biologics SA | Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| DE60144353D1 (de) | 2000-02-28 | 2011-05-12 | Novartis Vaccines & Diagnostic | Hybride Expression Neisserscher Proteine |
| CA2402602A1 (en) * | 2000-03-10 | 2001-09-13 | Edouard Bingen | Polynucleotides which are of nature b2/d+ a- and which are isolated from e. coli, and biological uses of these polynucleotides and of their polypeptides |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| CA2414884A1 (en) | 2000-07-03 | 2002-01-10 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
| JP4341949B2 (ja) | 2000-09-01 | 2009-10-14 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | アザ複素環式誘導体およびその治療的使用 |
| PL211125B1 (pl) | 2000-09-11 | 2012-04-30 | Novartis Vaccines & Diagnostic | Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie |
| CA2423487C (en) | 2000-09-26 | 2015-12-15 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| WO2002059320A2 (en) * | 2000-10-19 | 2002-08-01 | Wisconsin Alumni Research Foundation | Dna sequences of escherichia coli cft073 |
| IL154853A0 (en) | 2000-10-27 | 2003-10-31 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a & b |
| US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
| US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| UA75622C2 (en) | 2000-12-08 | 2006-05-15 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon |
| US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
| US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
| US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| GB0103424D0 (en) | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| MXPA03008154A (es) | 2001-03-09 | 2004-11-12 | Id Biomedical Corp Quebec | Novedoso adyuvante de vacuna de proteosoma-liposacarido. |
| WO2002077183A2 (en) * | 2001-03-21 | 2002-10-03 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| AU2002330681C1 (en) | 2001-07-26 | 2015-04-02 | Glaxosmithkline Biologicals S.A. | Vaccines comprising aluminium adjuvants and histidine |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| EP2196217A1 (en) | 2001-09-14 | 2010-06-16 | Cytos Biotechnology AG | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| CA2492823A1 (en) | 2001-09-14 | 2003-03-27 | Martin F. Bachmann | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| US7321033B2 (en) | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
| IL162137A0 (en) | 2001-11-27 | 2005-11-20 | Anadys Pharmaceuticals Inc | D-ribofuranosylthiazolo -3-Ä4,5-dÜpyridimine nucl eosides and uses thereof |
| US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US20030165870A1 (en) | 2002-03-01 | 2003-09-04 | Blattner Frederick R. | Novel sequences of E. coli CFT073 |
| EP1342784A1 (en) | 2002-03-06 | 2003-09-10 | Mutabilis S.A. | ExPEC-specific proteins, genes encoding them and uses thereof |
| ATE447404T1 (de) | 2002-03-29 | 2009-11-15 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
| AU2003233519A1 (en) | 2002-05-29 | 2003-12-19 | 3M Innovative Properties Company | Process for imidazo(4,5-c)pyridin-4-amines |
| FR2842210B1 (fr) * | 2002-07-09 | 2012-12-14 | Mutabilis | Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique |
| CN1688573A (zh) | 2002-08-23 | 2005-10-26 | 希龙公司 | 糖原合成酶激酶3的吡咯基抑制剂 |
| HUE047780T2 (hu) | 2002-10-11 | 2020-05-28 | Glaxosmithkline Biologicals Sa | Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| US20040209370A1 (en) | 2002-12-19 | 2004-10-21 | Wonchul Suh | Method for chromosomal engineering |
| WO2004060308A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Thiosemicarbazones as anti-virals and immunopotentiators |
| WO2004064759A2 (en) | 2003-01-21 | 2004-08-05 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
| GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
| EP1441036A1 (en) | 2003-01-27 | 2004-07-28 | Université de Nantes | Method for the identification and isolation of strong bacterial promoters |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| US20100255002A1 (en) | 2003-06-26 | 2010-10-07 | Chiron Corporation | Immunogenic compositions for chlamydia trachomatis |
| JP4049045B2 (ja) | 2003-07-28 | 2008-02-20 | トヨタ自動車株式会社 | 蓄熱装置付きエンジンシステム |
| EP1721283B1 (en) | 2004-02-06 | 2022-11-30 | Council of Scientific and Industrial Research | Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential |
| RU2006134631A (ru) | 2004-03-02 | 2008-04-10 | Чирон Корпорейшн (Us) | Иммуногенные композиции против chlamidia pneumoniae |
| SI2351772T1 (sl) | 2005-02-18 | 2016-11-30 | Glaxosmithkline Biologicals Sa | Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso |
-
2006
- 2006-02-17 SI SI200632108A patent/SI2351772T1/sl unknown
- 2006-02-17 ES ES11150423.9T patent/ES2595363T3/es active Active
- 2006-02-17 EP EP11150423.9A patent/EP2351772B1/en active Active
- 2006-02-17 DK DK11150423.9T patent/DK2351772T3/en active
- 2006-02-17 SG SG201001049-4A patent/SG160329A1/en unknown
- 2006-02-17 LT LTEP11150423.9T patent/LT2351772T/lt unknown
- 2006-02-17 NZ NZ561042A patent/NZ561042A/en not_active IP Right Cessation
- 2006-02-17 HU HUE11150423A patent/HUE030881T2/en unknown
- 2006-02-17 CA CA002601924A patent/CA2601924A1/en not_active Abandoned
- 2006-02-17 SI SI200632047A patent/SI1858920T1/sl unknown
- 2006-02-17 ES ES06748228.1T patent/ES2569654T3/es active Active
- 2006-02-17 PL PL06748228.1T patent/PL1858920T3/pl unknown
- 2006-02-17 DK DK06748228.1T patent/DK1858920T3/en active
- 2006-02-17 HU HUE06748228A patent/HUE027400T2/en unknown
- 2006-02-17 US US11/884,812 patent/US8758764B2/en active Active
- 2006-02-17 WO PCT/US2006/005913 patent/WO2006089264A2/en not_active Ceased
- 2006-02-17 PT PT111504239T patent/PT2351772T/pt unknown
- 2006-02-17 EP EP06748228.1A patent/EP1858920B1/en active Active
- 2006-02-17 NZ NZ597685A patent/NZ597685A/en not_active IP Right Cessation
- 2006-02-17 PL PL11150423T patent/PL2351772T3/pl unknown
- 2006-02-17 JP JP2007556383A patent/JP2008529558A/ja active Pending
- 2006-02-17 AU AU2006214064A patent/AU2006214064B2/en not_active Ceased
-
2007
- 2007-08-17 MX MX2007010043A patent/MX306302B/es active IP Right Grant
- 2007-08-19 IL IL185359A patent/IL185359A0/en unknown
-
2010
- 2010-05-27 IL IL206012A patent/IL206012A0/en unknown
-
2012
- 2012-01-20 NZ NZ597769A patent/NZ597769A/xx not_active IP Right Cessation
- 2012-05-22 JP JP2012116975A patent/JP2012152228A/ja active Pending
-
2014
- 2014-06-02 US US14/293,967 patent/US9334313B2/en active Active
-
2016
- 2016-04-27 CY CY20161100359T patent/CY1117732T1/el unknown
- 2016-05-09 US US15/150,204 patent/US10035826B2/en active Active
- 2016-10-12 CY CY20161101016T patent/CY1118149T1/el unknown
-
2018
- 2018-06-26 US US16/019,365 patent/US20180298064A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008529558A5 (OSRAM) | ||
| JP2008530245A5 (OSRAM) | ||
| US20230381301A1 (en) | Respiratory virus nucleic acid vaccines | |
| JP2010500399A5 (OSRAM) | ||
| ES2612741T3 (es) | Proteínas de fusión proteína n de un virus de la familia paramyxoviridae-proteína de interés | |
| JP2006149406A5 (OSRAM) | ||
| JP2006187292A5 (OSRAM) | ||
| JP2013507907A5 (OSRAM) | ||
| JP2008538183A5 (OSRAM) | ||
| JP2008525033A5 (OSRAM) | ||
| JP2010516290A5 (OSRAM) | ||
| TWI621627B (zh) | 用於豬生殖與呼吸綜合症及豬環狀病毒關聯疾病之疫苗組成物 | |
| JP2015509707A5 (OSRAM) | ||
| JP2007502101A5 (OSRAM) | ||
| RU2009123028A (ru) | F-белок респираторно-синцитиального вируса (rsv) и его применение | |
| US20250000968A1 (en) | Sars-cov-2 spike fused to a hepatitis b surface antigen | |
| JP2009520758A5 (OSRAM) | ||
| JP2010532656A5 (OSRAM) | ||
| WO2023051701A1 (zh) | 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗 | |
| HRP20130022T1 (hr) | Fuzijski proteini koji sadrže antigene ny-eso-1 i lage-1 za odbacivanje tumora | |
| JP2012506699A5 (OSRAM) | ||
| JP2020509770A5 (OSRAM) | ||
| EP2172488A1 (en) | Material with immunogenicity | |
| JP2005512518A5 (OSRAM) | ||
| ES2551699T3 (es) | Composiciones, procedimientos y kits |